Clinical phenotypes of Italian and Spanish patients with α1-antitrypsin deficiency

European Respiratory Journal

Volumn 42, Issue 1, 2013, Pages 54-64

  Piras, Barbara ^a,b   Ferrarotti, Ilaria ^c,d   Lara, Beatriz ^d,e   Martinez, Maria Teresa ^f   Bustamante, Ana ^g   Ottaviani, Stefania ^c   Pirina, Pietro ^a,b   Luisetti, Maurizio ^c,d   Miravitlles, Marc ^d,h  

^a UNIVERSITY OF SASSARI   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF PAVIA   (Italy)

^d Alpha One International Registry ^*  (Italy)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL SIERRALLANA   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RESPIRATORY TRACT AGENT;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; ASTHMA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; EMPHYSEMA; ETHNIC AND RACIAL GROUPS; FEMALE; GENOTYPE; HUMAN; ITALIAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SMOKING HABIT; SPANISH; TOBACCO;

ADULT; AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; SMOKING; SPAIN; YOUNG ADULT;

EID: 84878676391     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00104712     Document Type: Article

References (40)

1. Stoller JK, Aboussouan LS. A review of a1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185: 246-259.
2. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818-900.
3. Blanco I, De Serres FJ, Fernández-Bustillo E, et al. Estimated numbers and prevalence of PI*S and PI*Z alleles of a1-antitrypsin deficiency European countries. Eur Respir J 2006; 27: 77-84. (Pubitemid 43092670)
4. Luisetti M, Seersholm N. Alpha1-antitrypsin deficiency 1: epidemiology of alpha1-antitrypsin deficiency. Thorax 2004; 59: 164-169.
5. Leiden Open Variation Database. Serpina 1 homepage. https://research. cchmc.org/LOVD2/home.php?select-db5SERPINA1 Date last accessed: September 10, 2012. Date last updated: May 6, 2010.
6. National Center for Biotechnology Information (NCBI). dbSNP Short Genetic Variations. www.ncbi.nlm.nih.gov/SNP/snp-ref.cgi?locusId55265 Date last accessed: September 10, 2012.
7. Laurell CB, Eriksson A. The electrophoretic a-1 globulin pattern of serum in a-1 antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 132-140.
8. Miravitlles M, Vidal R, Barros-Tizón JC, et al. Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir Med 1998; 92: 1181-1187. (Pubitemid 28502358)
9. Stoller JK, Brantly M, Fleming LE, et al. Formation and current results of a patient-organized registry for alpha(1)-antitrypsin deficiency. Chest 2000; 118: 843-848.
10. Alpha1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 1997; 75: 397-415.
11. Stockley RA, Luisetti M, Miravitlles M, et al. Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development. Eur Respir J 2007; 29: 582-586. (Pubitemid 46379103)
12. Rachelefsky G, Hogarth DK. Issues in the diagnosis of alpha 1-antitrypsin deficiency. J Allergy Clin Immunol 2008; 121: 833-838.
13. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.org/guidelines-global-strategy-fordiagnosis- management.html Date last accessed: July 10, 2012. Date last updated: February 2013.
14. Lara B, de la Roza C, Vilà S, et al. Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2007; 2: 393-398. (Pubitemid 350110913)
15. Lara B, Morales P, Blanco I, et al. Registros de enfermedades respiratorias en España: fundamentos y organizació n. [Respiratory disease registries in Spain: fundamentals and organization.]. Arch Bronconeumol 2011; 47: 389-396.
16. Luisetti M, Massi G, Massobrio M, et al. A national program for detection of alpha 1-antitrypsin deficiency in Italy. Gruppo I.D.A. Respir Med 1999; 93: 169-172. (Pubitemid 29090049)
17. Ferrarotti I, Scabini R, Campo I, et al. Laboratory diagnosis of alpha1-antitrypsin deficiency. Transl Res 2007; 150: 267-274.
18. De la Roza C, Rodríguez-Frías F, Lara B, et al. Results of a case-detection programme for alpha-1-antitrypsin deficiency in COPD patients. Eur Respir J 2005; 26: 616-622. (Pubitemid 41448658)
19. Miravitlles M, Herr C, Ferrarotti I, et al. Laboratory testing of individuals with severe alpha 1-antitrypsin deficiency in three European Centres. Eur Respir J 2010; 35: 960-968.
20. McElvaney NG, Stoller JK, Buist AS, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111: 394-403. (Pubitemid 27096957)
21. Stoller JK, Sandhaus RA, Turino G, et al. Delay in diagnosis of alpha-1 antitrypsin deficiency. A continuing problem. Chest 2005; 128: 1989-1994. (Pubitemid 41507532)
22. Köhlein T, Janciauskiene S, Welte T. Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency. Ther Adv Respir Dis 2010; 4: 279-287.
23. Molina J, Flor X, García R, et al. The IDDEA project: a strategy for the detection of alpha-1 antitrypsin deficiency in COPD patients in the primary care setting. Ther Adv Respir Dis 2011; 5: 237-243.
24. Rodriguez-Frias F, Miravitlles M, Vidal R, et al. Rare alpha-1-antitrypsin variants: are they really so rare? Ther Adv Respir Dis 2012; 6: 79-85.
25. Ferrarotti I, Baccheschi J, Zorzetto M, et al. Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency. J Med Genet 2005; 42: 282-287. (Pubitemid 40380312)
26. Tonelli AR, Brantly ML. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. Ther Adv Respir Dis 2010; 4: 289-312.
27. Vidal R, Blanco I, Casas F, et al. Diagnó stico y tratamiento del deficit de alfa-1-antitripsina. [Guidelines for the diagnosis and management of alpha-1 antitrypsin deficiency.]. Arch Bronconeumol 2006; 42: 645-659. (Pubitemid 46132369)
28. Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha-1 antitrypsin deficiency with special reference to non-index cases. Thorax 1994; 49: 695-698. (Pubitemid 24219149)
29. Silverman EK, Pierce JA, Province MA, et al. Variability of pulmonary function in alpha-1 antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111: 982-991. (Pubitemid 20034922)
30. Han MK, Agustí A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
31. Miravitlles M, Calle M, Soler-Cataluña JJ. Fenotipos clínicos de la EPOC. Identificació n, definición e implicaciones para las guías de tratamiento. [Clinical phenotypes of COPD: identification, definition and implications for guidelines.]. Arch Bronconeumol 2012; 48: 86-98.
32. Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011; 12: 127.
33. Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176: 1215-1221. (Pubitemid 350256475)
34. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Guía Española de la EPOC (GesEpoc). Tratamiento farmacoló gico de la EPOC estable. [Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.]. Arch Bronconeumol 2012; 48: 247-257.
35. Dahl M, Hersh CP, Ly NP, et al. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J 2005; 26: 67-76. (Pubitemid 40945933)
36. Bartmann K, Fooke-Achterrath M, Koch G, et al. Heterozygosy in the Pi-system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD). Eur J Respir Dis 1985; 66: 284-296. (Pubitemid 15106351)
37. Holme J, Stockley RA. CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha-1 antitrypsin deficiency. Chest 2009; 136: 1284-1290.
38. Ferrarotti I, Thun GA, Zorzetto M, et al. Serum levels and genotype distribution of a1-antitrypsin in the general population. Thorax 2012; 67: 669-674.
39. Tirado-Conde G, Lara B, Casas F, et al. Factores asociados a la evolución de la function pulmonary en pacientes con deficit de alfa-1-antitripsina del registro español. [Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish registry.]. Arch Bronconeumol 2011; 47: 495-503.
40. Luisetti M, Balfour-Lynn IM, Johnson SR, et al. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Respir Med 2012; 106: 759-768.